Entering text into the input field will update the search result below

ImmunoGen inks deal with Takeda for cancer drug Elahere

Aug. 28, 2023 7:12 AM ETImmunoGen, Inc. (IMGN), TAK, TKPHFBy: Dulan Lokuwithana, SA News Editor5 Comments
Collaboration concept in word tag cloud


  • ImmunoGen (NASDAQ:IMGN) traded higher in the pre-market Monday after the biotech announced a partnership with Takeda Pharmaceutical (NYSE:TAK) to develop and commercialize its lead cancer therapy, Elahare, in Japan.
  • Per the terms, Takeda (TAK) will receive an exclusive license

Recommended For You

Comments (5)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

Longs will be rewarded. There are some historical correlates. GILD purchased Immunomedics whose share price skyrocketed to the 80s, and Pfizer bought Array pharmaceuticals. Unless there is something nobody knows about, see a buyout sometime in the near future.
IMGN potential grand slam, catalysts ahead.
$TAK excellent co and marketing. However, stock price doesn’t reflect where it should be closer towards 20-25
@deadhead213 curious to know more about how you see it at that price. I’m having trouble valuing the company
@TrufflePigGunSlinger huge distributor, lots of cash reserves. Stock hasn’t moved in 3-4 years. Excellent dividend, stock extremely undervalued

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.